Results for tag: "Diabetes Associated Ophthalmic Treatment"

The Diabetes Associated Ophthalmic Treatment market encompasses a range of medical procedures, devices, and medications utilized in the management and care of eye conditions associated with diabetes, specifically diabetic retinopathy and diabetic macular edema. Diabetic retinopathy involves changes to retinal blood vessels that can cause them to bleed or leak fluid, distorting vision. Treatments for these conditions range from laser surgery to control bleeding to the administration of anti-VEGF drugs, which help to reduce abnormal blood vessel growth and swelling. Intravitreal injections of steroids can also be utilized for their anti-inflammatory effects. Additionally, there is a growing interest in the development and use of novel drug delivery systems and surgical instruments to improve the precision and efficacy of treatments. Furthermore, technological advancements in optical coherence tomography (OCT) aids in the early detection and management of diabetic eye diseases by providing high-resolution images of the retina. Regular screening among diabetic patients is crucial for early intervention and has become an integral part of diabetes care, helping to prevent vision loss. Several companies have established positions in the market, which include Novartis, Roche, Regeneron Pharmaceuticals, Bayer, and Abbott. These companies are involved in the production of therapeutics like anti-VEGF injections, as well as manufacturing devices and supplies for laser treatments and surgeries tailored to mitigate the ocular complications that arise from diabetes. Show Less Read more